Washington,
DC, November 12, 2003---A major report on testosterone research needs
was released today by the Institute of Medicine (IOM), the medical branch
of the National Academy of Sciences. After several years of study, the
blue-ribbon panel recommended to the NIH that future studies should
be small, focused ‘Phase II types,’rather than large ‘Phase
III types’, and that emphasis should be on the “nature and
extent of potential benefits.” Further, the panel recommended
| A large-scale trial
to determine long-term risks and effectiveness should be undertaken
only if clinically significant benefits are demonstrated in the
initial, shorter studies. The studies should involve only older
men who have been diagnosed with low testosterone levels and at
least one symptom that might be remedied by the therapy, and who
are not at high risk for developing prostate cancer |
This report is of great interest at Urological Sciences
Research Foundation (USRF) because just
such a project is currently underway now in the Los Angeles offices
of USRF
The report further said currently available evidence suggests
that testosterone therapy may have potential benefit for older men in
terms of improving strength, sexual function, cognitive function, and
general well-being. The committee found no compelling evidence of major
adverse side effects resulting from testosterone therapy, but the evidence
is inadequate to document safety, the report says.
Testosterone information now available is limited to short
studies in small groups of men. The need for testosterone information
in older men is great, because according to the Census Bureau, there
are now in the U.S. nearly 15 million men over the age of 65, and this
number is expected to grow. to 17 million by 2010. Testosterone usage
appears to be growing rapidly, partly due to improved
delivery systems. More than 1.75 million prescriptions for testosterone
therapy were written in 2002, a 30% jump from 2001.
The IOM report was commissioned by the National
Institute of Aging and the National
Cancer Institute. The IOM is the medical
branch of the National Academy of Sciences (NAS), which is the nation’s
premier advisory body regarding the establishment of priorities and
allocation of resources in the sciences. The NAS was signed into being
in 1863 by President Abraham Lincoln with a mission to "investigate,
examine, experiment, and report upon any subject of science or art"
whenever called upon to do so by any department of the government.
ADDITIONAL RELATED LINKS:
|